"The first stock of AI pharmaceutical delivery" Hengtai Technology officially passed the hearing of the Hong Kong Stock Exchange.

"AI drug delivery first stock" JiTai Technology officially passed the hearing of the Hong Kong Stock Exchange. According to its prospectus, the funds raised this time are intended to be used for AI infrastructure and nanomaterial platform technology research and development, advancing clinical trials in the research pipeline, and applications in the field of animal health and anti-aging. The company's revenue in 2025 reached 105 million yuan, compared to 1.5 million yuan in 2024 and 9.3 million yuan in 2023, a nearly 70-fold increase. The gross profit margin increased from 55.5% in 2024 to 98.2% in 2025. The annual loss narrowed from 499 million yuan in 2024 to 392 million yuan in 2025, and the adjusted net loss decreased from 347 million yuan in 2023 to 180 million yuan in 2025. As of December 31, 2025, JiTai Technology held a total of 1.13 billion yuan in cash and cash equivalents, time deposits, and financial assets measured at fair value.